Sinovac Biotech 주식 가격. SVA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Sinovac Biotech Ltd (SVA) 시세

Sinovac Biotech Ltd (SVA)

6.47

0.00

(0.00%)

마감 19 11월 6:00AM

6.47

0.00

( 0.00% )

시간외 단일가: 9:00AM

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

가격

6.47

매수가

6.47

매도가

6.16

거래량

-

0.00 일간 변동폭 0.00

6.47 52주 범위 6.47

market_cap

전일 종가

6.47

개장가

-

최근 거래 시간

마지막 거래 시간

-

재정 규모

-

VWAP

-

평균 볼륨(3m)

-

발행 주식

71,139,402

배당수익률

-

주가수익률

-1.78

주당순이익(EPS)

-3.63

매출

448.27M

순이익

-258.36M

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), ... Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.sinovac.com

본부

Saint John, Atg

설립됨

-

Sinovac Biotech Ltd is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker SVA. The last closing price for Sinovac Biotech was US$6.47. Over the last year, Sinovac Biotech shares have traded in a share price range of US$ 6.47 to US$ 6.47.

Sinovac Biotech currently has 71,139,402 shares in issue. The market capitalisation of Sinovac Biotech is US$460.27 million. Sinovac Biotech has a price to earnings ratio (PE ratio) of -1.78.

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

SINOVAC Reports Unaudited First Half of 2024 Financial Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities...

Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder...

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

シノバック取締役会、一方的な部分公開買い付けを全会一致で退ける

取締役会は全会一致で、シノバック株主に対し、買付提案に基づく株式の買付に応じないよう勧告する（ビジネスワイヤ） -- 中国のバイオ医薬品におけるリーディングプロバイダーであるシノバック・バイオテ...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	6.47	6.47	6.47	0	0	CS
4	0	0	6.47	6.47	6.47	0	0	CS
12	0	0	6.47	6.47	6.47	0	0	CS
26	0	0	6.47	6.47	6.47	0	0	CS
52	0	0	6.47	6.47	6.47	0	0	CS
156	0	0	6.47	6.47	6.47	0	0	CS
260	0	0	6.47	6.47	6.47	0	0	CS

가장 활성
% 상승자
% 패자

기호	가격	볼륨
NCNCnoco noco Inc	US$ 0.265 (173.20%)	23.3M
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 46.18 (80.96%)	63.89k
CTRNCiti Trends Inc	US$ 22.97 (40.70%)	2
BCALCalifornia BanCorp	US$ 24.01 (39.51%)	100
SMCISuper Micro Computer Inc	US$ 30.04 (39.46%)	2.44M
IBCPIndependent Bank Corporation	US$ 28.25 (-23.65%)	4
PNTGPennant Group Inc	US$ 25.21 (-20.20%)	3
CMPRCimpress PLC	US$ 63.73 (-17.06%)	151
ADGMAdagio Medical Holdings Inc	US$ 2.35 (-13.92%)	25
NIVFNewGenIvf Group Ltd	US$ 0.5005 (-13.71%)	37.92k
NCNCnoco noco Inc	US$ 0.265 (173.20%)	23.3M
SMCISuper Micro Computer Inc	US$ 30.04 (39.46%)	2.44M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 20.20 (-2.74%)	1.35M
ELABElevai Labs Inc	US$ 0.0221 (-3.49%)	1.05M
HCWBHCW Biologics Inc	US$ 1.17 (-5.65%)	520.37k

AlternativeLiquidity

AlternativeLiquidity 10 월 전

Tender offer for Sinovac Shares:
https://www.sec.gov/Archives/edgar/data/1084201/000187041224000001/0001870412-24-000001-index.htm

Investor Letter:
https://www.sec.gov/Archives/edgar/data/1084201/000187041224000001/Exhibit_A3.htm

For investors that are sick of holding the shares, this might be a good opportunity to exit.

Annual reports and other public disclosures from the company are available here:

https://www.sec.gov/edgar/browse/?CIK=0001084201

mick

mick 11 월 전

https://www.otcmarkets.com/stock/SVA

mick

mick 11 월 전

https://www.otcmarkets.com/stock/SVA

mick

https://www.otcmarkets.com/stock/SVA

mick

https://www.otcmarkets.com/stock/SVA

IHuser

IHuser 1 년 전

imo... i guarantee my following will destroy this ticker....quickly...SVA

IHuser

IHuser

IHuser 1 년 전

imo... ya mick me and my boys own this market now.....gl...wont be a market soon~

IHuser

mick

https://www.otcmarkets.com/stock/SVA

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

mick

Date

Event

January 28, 2020

SINOVAC established and launched a new COVID-19 vaccine research and development project

June 13, 2020

SINOVAC announced a Phase I/II clinical study of its new COVID-19 vaccine, showing the vaccine was safe and effective in producing neutralizing antibodies

February 16, 2021

Professor Lau Chak-sing, Convener of the Hong Kong Vaccine Advisory Expert Committee, announced the committee’s review of data for CoronaVac®. Results showed CoronaVac® benefits outweigh the risks. The committee recommended the vaccine to the government

February 19, 2021

Within 72 hours after the advisory committee's recommendation, the first batch of one million doses of CoronaVac® arrived in Hong Kong from Beijing. Hong Kong subsequently launched a large-scale COVID-19 vaccination program

June 2, 2022

CoronaVac® was validated by the World Health Organization’s Emergency Use List Procedure

February 20, 2022

SINOVAC Foundation donations to Hong Kong helped local communities in the fight against the COVID-19 pandemic

April 14, 2022

In cooperation with HKU and Gleneagles Hospital, SINOVAC’s inactivated COVID-19 vaccine (omicron variant) was approved for clinical trials in Hong Kong

August 4, 2022

Children between the ages of 6 months and 3 years old were eligible for receiving CoronaVac®. To help the public complete their vaccinations as soon as possible, Hong Kong had opened up multiple new vaccination centers.

December 16, 2022

CoronaVac® was fully registered in Hong Kong under the Pharmacy and Poisons Ordinance Cap 138. It is one of the first COVID-19 vaccines approved for official registration in Hong Kong

May 10, 2023

SINOVAC announced the supply of the inactivated COVID-19 vaccine CoronaVac® (original strain) to Hong Kong’s private market, with plans to donate free COVID-19 vaccines to children

[1] HKSAR news.gov.hk: Professor Lo Chung Mo’s Chinese article dated 15 Sept 2022. https://www.news.gov.hk/chi/2022/09/20220915/20220915_145920_647.html

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005485/en/

Sinovac Biotech Ltd.
PR Team
pr@sinovac.com

mick

decrease in sales <> https://www.otcmarkets.com/filing/html?id=16605858&guid=_1T-knRCUJRXB3h

mick

interesting review <> https://ih.advfn.com/stock-market/NASDAQ/sinovac-biotech-SVA/stock-news/91160230/amended-statement-of-beneficial-ownership-sc-13d-a

$SVA

mick

Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 05/25/2023 11:14:28 AM
CoronaVac® von SINOVAC erfüllt Hongkongs Bedarf an COVID-19-Impfstoffen zur Selbstzahlung • Business Wire • 05/12/2023 04:22:00 PM
??????CoronaVac ®????????????COVID-19????????????????? • Business Wire • 05/10/2023 06:02:00 PM
Le vaccin CoronaVac® de SINOVAC répond au besoin pour des vaccins contre la COVID-19 autopayés à Hong Kong • Business Wire • 05/10/2023 06:02:00 PM

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

mick

Sinovac ändert Plan für Aktionärsrechte • Business Wire • 02/22/2023 03:20:00 PM
Amended Securities Registration (section 12(b)) (8-a12b/a) • Edgar (US Regulatory) • 02/22/2023 11:31:40 AM

mick

Recent SVA News
???????????????? • Business Wire • 02/23/2023 12:38:00 PM
Sinovac modifie le régime de droits des actionnaires • Business Wire • 02/22/2023 05:02:00 PM
Sinovac ändert Plan für Aktionärsrechte • Business Wire • 02/22/2023 03:20:00 PM
Amended Securities Registration (section 12(b)) (8-a12b/a) • Edgar (US Regulatory) • 02/22/2023 11:31:40 AM

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

mick

$SVA http://www.sinovac.com/

mick

SINOVAC Reports Unaudited First Half of 2022 Financial ResultsBUSINESS WIRE | 12/29/2022

mick

FORM TYPE RECEIVED PERIOD END DATE REPORT
6-K 12/29/2022 12/29/2022 PDFRTFHTMLXLS
SC 13D/A 12/12/2022 PDFRTFHTMLXLS
6-K 11/04/2022 11/04/2022 PDFRTFHTML
6-K 06/09/2022 06/09/2022 PDFRTFHTML
6-K 05/06/2022 05/06/2022 PDFRTFHTML
6-K 05/02/2022 04/29/2022 PDFRTFHTMLXLS
20-F 04/29/2022 12/31/2021 PDFRTFHTMLXLS
8-A12B/A 02/22/2022 PDFRTFHTMLXLS
6-K 02/22/2022 02/22/2022 PDFRTFHTML
6-K 12/30/2021 12/30/2021 PDFRTFHTMLXLS

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -

mick

SVA Latest News
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 12/29/2022 08:41:47 AM
SINOVAC Reports Unaudited First Half of 2022 Financial Results 12/29/2022 08:30:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) 12/12/2022 06:45:09 AM
?????????????WHO???????? 11/04/2022 08:01:00 AM

mick

https://www.otcmarkets.com/stock/SVA/security

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume:

mick

https://www.otcmarkets.com/stock/SVA/disclosure

mick

Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM

mick

Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)

mick

Recent SVA News
???????????????COVID-19????????????????????? • Business Wire • 09/07/2022 11:57:00 AM
SINOVAC erhält Genehmigung für klinische Studie zu seinem Omikron-COVID-19-Impfstoff in Chile • Business Wire • 09/06/2022 07:20:00 PM
SINOVAC autorisé à lancer au Chili un essai clinique pour son vaccin contre le variant Omicron du Covid-19 • Business Wire • 09/06/2022 02:03:00 PM

mick

https://www.nytimes.com/2020/12/25/health/turkey-brazil-sinovac-coronavirus-vaccine.html?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link
Turkey signed a deal with Sinovac for 50 million doses of the vaccine. The first three million doses are scheduled to arrive Monday in Turkey,
Mr. Koca said. Mr. Koca said Turkey would also get 4.5 million doses of the Pfizer-BioNTech vaccine by the end of March.
Around 1 million doses are expected to arrive at the end of January, he said.

mick

Contact: Stella Wang
Email: http://www.Stellawang@1globe-china.com

mick

Contact: Stella Wang
Email: http://www.Stellawang@1globe-china.com

mick

http://www.sinovac@sinovac.com

mick

http://www.pr@sinovac.com

mick

Recent SVA News
??????COVID-19??????????6????????????????? • Business Wire • 08/05/2022 06:19:00 PM
L'utilisation du vaccin anti-COVID-19 de SINOVAC approuvée à partir de l'âge de six mois à Hong Kong • Business Wire • 08/03/2022 04:45:00 PM
COVID-19-Impfstoff von SINOVAC in Hongkong zur Verwendung bei Kindern ab einem Alter von 6 Monaten zugelassen • Business Wire • 08/03/2022 04:45:00 PM
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong • Business Wire • 08/03/2022 10:00:00 AM
?????????4???????????????????? • Business Wire • 07/20/2022 12:00:00 PM
SINOVAC startet klinische Studie für seinen Vierfach-Grippeimpfstoff in Chile • Business Wire • 07/19/2022 01:31:00 PM
SINOVAC lance un essai clinique au Chili pour son vaccin antigrippal quadrivalent • Business Wire • 07/19/2022 11:16:00 AM

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
Bid: 6.93
Ask: 6.00
SVA Detailed Quote

mick

SVA
Sinovac Biotech Ltd
6.47
0.00 (0.00%)
Volume: -
Bid: 6.93
Ask: 6.10
SVA Detailed Quote

mick

https://www.otcmarkets.com/stock/SVA/overview

mick

https://www.otcmarkets.com/stock/SVA/overview

mick

never answered e-mail $SVA

mick

yes hope it does $SVA

mick

$SVA News: COVID-19-Impfstoff von SINOVAC erhält in Brasilien Notfallzulassung für Kinder im Alter von 3 bis 5 Jahren 07/14/2022 01:36:00 PM
SVA News: Le vaccin SINOVAC contre le COVID-19 est autorisé pour une utilisation d’urgence chez les enfants âgés de 3 à 5 ans au Brésil 07/14/2022 01:00:00 PM

mick

$SVA News: SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil 07/14/2022 11:02:00 AM

mick

$SVA News: SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil 07/14/2022 05:10:00 AM
SVA News: SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa 06/25/2022 12:30:00 AM

Sinovac Biotech

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관